Your personal cancer intelligence.

Always available, grounded in evidence, designed to help you understand your options.

A cancer diagnosis comes with an overwhelming flood of information — most of it generic, little of it personalized to your specific case.

You deserve an intelligence that understands your cancer type, your mutations, and your treatment history — and can help you make sense of the research that matters most to you.

Evidence-grounded answers

Ask questions about your cancer type, treatments, or side effects and receive responses traced to peer-reviewed research and clinical data.

Understands your case

Galen learns your cancer type, mutations, and treatment history to surface the most relevant findings for your specific situation.

Monitors new research

As new studies and trials are published, Galen identifies what may be relevant to you and surfaces it proactively.

Every source cited

Every finding is labeled with its evidence tier — clinical, research, or computational — so you always know what supports each claim.

Understands why, not just what

Galen traces how specific mutations drive cancer behavior, how treatments work at the molecular level, and why resistance might develop — so you can understand the science behind your case, not just the conclusions.

Every answer traced to its source

No guessing. Every answer is linked to the research behind it.

What are the treatment options for my type of lung cancer?

Based on your cancer profile, here are your main treatment options:

Osimertinib — commonly used first-line treatmentFLAURA2 Trial, NEJM 2023

Patients stayed cancer-free for an average of 18.9 months. The current go-to treatment for your type.

Chemotherapy + radiation togetherNCCN Guidelines v2.2024

Recommended when the tumor can't be removed by surgery.

Amivantamab + lazertinib (newer option)MARIPOSA Trial, 2024

A promising new drug combination being studied in clinical trials right now.

Digging deeper into your specific cancer:

How your cancer grows — the biological chain reactionGalen pathway analysis

Your mutation triggers a chain of signals that tells cancer cells to keep growing. This is what targeted drugs aim to block.

What to watch for: drug resistance develops in ~60% of casesOxnard et al., JCO 2018

Galen tracks new published research on resistance mechanisms relevant to your cancer type.

Try Galen for free.

50 free messages. No credit card required.